Luminex Corporation Company Profile (NASDAQ:LMNX)

About Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LMNX
  • CUSIP: 55027E10
  • Web: www.luminexcorp.com
Capitalization:
  • Market Cap: $902.68 million
  • Outstanding Shares: 43,926,000
Average Prices:
  • 50 Day Moving Avg: $20.83
  • 200 Day Moving Avg: $19.67
  • 52 Week Range: $17.64 - $23.75
P/E:
  • Trailing P/E Ratio: 63.63
  • Foreward P/E Ratio: 32.52
  • P/E Growth: 0.71
Sales & Book Value:
  • Annual Revenue: $285.44 million
  • Price / Sales: 3.15
  • Book Value: $9.51 per share
  • Price / Book: 2.15
Dividend:
  • Annual Dividend: $0.24
  • Dividend Yield: 1.2%
Profitability:
  • EBIDTA: $50.46 million
  • Net Margins: 5.00%
  • Return on Equity: 5.48%
  • Return on Assets: 4.98%
Debt:
  • Current Ratio: 5.79%
  • Quick Ratio: 4.34%
Misc:
  • Average Volume: 232,465 shs.
  • Beta: 0.29
  • Short Ratio: 9.92
 
Frequently Asked Questions for Luminex Corporation (NASDAQ:LMNX)

What is Luminex Corporation's stock symbol?

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex Corporation pay dividends? What is the dividend yield for Luminex Corporation?

Luminex Corporation declared a quarterly dividend on Thursday, May 25th. Shareholders of record on Friday, June 23rd will be given a dividend of $0.06 per share on Friday, July 14th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Wednesday, June 21st. View Luminex Corporation's Dividend History.

How were Luminex Corporation's earnings last quarter?

Luminex Corporation (NASDAQ:LMNX) released its quarterly earnings data on Monday, May, 1st. The company reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.16 by $0.12. The company had revenue of $77.80 million for the quarter, compared to the consensus estimate of $74.25 million. Luminex Corporation had a net margin of 5.00% and a return on equity of 5.48%. The firm's revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. View Luminex Corporation's Earnings History.

When will Luminex Corporation make its next earnings announcement?

Luminex Corporation is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Luminex Corporation.

Where is Luminex Corporation's stock going? Where will Luminex Corporation's stock price be in 2017?

6 analysts have issued twelve-month price objectives for Luminex Corporation's shares. Their predictions range from $18.00 to $27.00. On average, they anticipate Luminex Corporation's stock price to reach $21.40 in the next twelve months. View Analyst Ratings for Luminex Corporation.

What are analysts saying about Luminex Corporation stock?

Here are some recent quotes from research analysts about Luminex Corporation stock:

  • 1. According to Zacks Investment Research, "Luminex’s Assay business will be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory-front of late. In this regard, the reimbursement approval of VERIGENE assay in Japan and FDA clearance of Bordetella Assay are noteworthy. We are also optimistic about the company’s products – ARIES and NxTAG RPP – which represent a major revenue opportunity.  Luminex reported stable first-quarter 2017 results, beating the Zacks Consensus Estimates on both lines. Also the weakness in stock price over the past on year has made valuation very compelling. Finally Luminex has a broad product portfolio that comprises of its advanced xMAP, xTAG and MultiCode technology. The company’s large installed instrument base and collaborative agreements with several companies would also help expand the use of its products." (7/17/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex Corporation's key competitors?

Who are Luminex Corporation's key executives?

Luminex Corporation's management team includes the folowing people:

  • G. Walter Loewenbaum II, Independent Chairman of the Board
  • Nachum Shamir, President, Chief Executive Officer, Director
  • Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
  • Richard W. Rew II, Senior Vice President, General Counsel, Secretary
  • Nancy M. Fairchild, Senior Vice President - Human resources
  • Randall Myers, Senior Vice President - Global Manufacturing and Quality
  • Robert J. Cresci, Independent Director
  • Stephen L Eck, Independent Director
  • Thomas Willard Erickson, Independent Director
  • Jimmy Dale Kever, Independent Director

Who owns Luminex Corporation stock?

Luminex Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Villere ST Denis J & Co. LLC (6.14%), Acadian Asset Management LLC (2.06%), Thomson Horstmann & Bryant Inc. (0.94%), CWM LLC (0.41%), Benjamin F. Edwards & Company Inc. (0.20%) and Fisher Asset Management LLC (0.15%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Who sold Luminex Corporation stock? Who is selling Luminex Corporation stock?

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Acadian Asset Management LLC, CWM LLC, Russell Investments Group Ltd., Bank of Montreal Can, Municipal Employees Retirement System of Michigan, Capstone Asset Management Co. and Creative Planning. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara. View Insider Buying and Selling for Luminex Corporation.

Who bought Luminex Corporation stock? Who is buying Luminex Corporation stock?

Luminex Corporation's stock was bought by a variety of institutional investors in the last quarter, including Aperio Group LLC, Fisher Asset Management LLC, Thomson Horstmann & Bryant Inc., State of Alaska Department of Revenue, Eqis Capital Management Inc., Strs Ohio, Benjamin F. Edwards & Company Inc. and Louisiana State Employees Retirement System. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

How do I buy Luminex Corporation stock?

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex Corporation's stock price today?

One share of Luminex Corporation stock can currently be purchased for approximately $20.49.


MarketBeat Community Rating for Luminex Corporation (NASDAQ LMNX)
Community Ranking:  1.2 out of 5 ()
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Luminex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Luminex Corporation (NASDAQ:LMNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $21.40 (4.44% upside)

Analysts' Ratings History for Luminex Corporation (NASDAQ:LMNX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017Jefferies Group LLCReiterated RatingHold$21.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016J P Morgan Chase & CoUpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
8/4/2015WedbushUpgradeNeutral -> Outperform$19.00 -> $22.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Luminex Corporation (NASDAQ:LMNX)
Earnings by Quarter for Luminex Corporation (NASDAQ:LMNX)
Earnings History by Quarter for Luminex Corporation (NASDAQ LMNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017$0.11N/AView Earnings Details
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Luminex Corporation (NASDAQ:LMNX)
2017 EPS Consensus Estimate: $0.24
2018 EPS Consensus Estimate: $0.45
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.06$0.06$0.06
Q3 20171$0.06$0.06$0.06
Q4 20171$0.03$0.03$0.03
Q1 20181$0.12$0.12$0.12
Q2 20181$0.11$0.11$0.11
Q3 20181$0.11$0.11$0.11
Q4 20181$0.11$0.11$0.11
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Luminex Corporation (NASDAQ:LMNX)
Most Recent Dividend:7/14/2017
Annual Dividend:$0.24
Dividend Yield:1.17%
Payout Ratio:75.00% (Trailing 12 Months of Earnings)
43.64% (Based on This Year's Estimates)
38.10% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex Corporation (NASDAQ:LMNX)

Dividend History by Quarter for Luminex Corporation (NASDAQ LMNX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/25/2017quarterly$0.061.18%6/21/20176/23/20177/14/2017
2/22/2017special$0.063/22/20173/24/20174/14/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Luminex Corporation (NASDAQ:LMNX)
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 77.20%
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.00View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.00View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.00View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.00View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.02View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.53View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Luminex Corporation (NASDAQ:LMNX)
Latest Headlines for Luminex Corporation (NASDAQ:LMNX)
Source:
DateHeadline
streetinsider.com logoLuminex Corp. (LMNX) Granted FDA Clearance for ARIES C. Difficile Assay
www.streetinsider.com - July 25 at 2:53 AM
finance.yahoo.com logoETFs with exposure to Luminex Corp. : July 24, 2017
finance.yahoo.com - July 25 at 2:53 AM
finance.yahoo.com logoLuminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
finance.yahoo.com - July 24 at 11:38 AM
finance.yahoo.com logoLuminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : July 24, 2017
finance.yahoo.com - July 24 at 11:38 AM
americanbankingnews.com logoHead to Head Review: LeMaitre Vascular (LMAT) versus Luminex Corporation (LMNX)
www.americanbankingnews.com - July 20 at 10:16 PM
finance.yahoo.com logoLuminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017
finance.yahoo.com - July 17 at 12:57 PM
americanbankingnews.com logoZacks Investment Research Upgrades Luminex Corporation (LMNX) to "Buy"
www.americanbankingnews.com - July 17 at 12:53 PM
finance.yahoo.com logoETFs with exposure to Luminex Corp. : July 14, 2017
finance.yahoo.com - July 15 at 6:01 AM
finance.yahoo.com logoLuminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : July 10, 2017
finance.yahoo.com - July 11 at 12:22 AM
americanbankingnews.com logoLuminex Corporation (NASDAQ:LMNX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 10 at 3:08 PM
americanbankingnews.com logoLuminex Corporation (NASDAQ:LMNX) Downgraded by ValuEngine
www.americanbankingnews.com - July 8 at 10:10 PM
americanbankingnews.com logo$75.18 Million in Sales Expected for Luminex Corporation (NASDAQ:LMNX) This Quarter
www.americanbankingnews.com - July 6 at 10:31 AM
americanbankingnews.com logoLuminex Corporation (NASDAQ:LMNX) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - July 4 at 6:24 PM
americanbankingnews.com logoLuminex Corporation (LMNX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 4 at 10:48 AM
streetinsider.com logoLuminex Corp. (LMNX) Announces Receipt of CE-IVD Mark for ARIES Norovirus Assay
www.streetinsider.com - June 30 at 11:46 PM
finance.yahoo.com logoLuminex Gets CE Mark for ARIES Norovirus Assay, Shares Rally
finance.yahoo.com - June 30 at 1:07 AM
finance.yahoo.com logoLuminex Corporation Receives CE-IVD Mark for ARIES® Norovirus Assay
finance.yahoo.com - June 28 at 7:57 PM
seekingalpha.com logoLuminex receives CE-IVD mark for ARIES Norovirus Assay
seekingalpha.com - June 28 at 9:04 AM
zacks.com logoConforMIS (CFMS) Gets FDA Approval for iTotal Hip System
www.zacks.com - June 26 at 9:24 AM
zacks.com logoEvolent Health (EVH) Prices 4.5M Follow-On Share Offering
www.zacks.com - June 23 at 7:46 AM
finance.yahoo.com logoETFs with exposure to Luminex Corp. : June 19, 2017
finance.yahoo.com - June 19 at 5:21 PM
finance.yahoo.com logoDENTSPLY (XRAY) Renews Partnership with Pacific Dental
finance.yahoo.com - June 19 at 11:49 AM
finance.yahoo.com logoLuminex Corp. :LMNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 7:14 PM
finance.yahoo.com logoCONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
finance.yahoo.com - June 14 at 10:24 AM
americanbankingnews.com logoLuminex Corporation (LMNX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 13 at 12:50 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Luminex Co. (LMNX) Will Announce Quarterly Sales of $75.18 Million
www.americanbankingnews.com - June 10 at 8:24 AM
americanbankingnews.com logoLuminex Co. (LMNX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - June 9 at 5:08 PM
americanbankingnews.com logoLuminex Co. (LMNX) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - June 8 at 4:30 PM
finance.yahoo.com logoFeatured Company News - Luminex's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan
finance.yahoo.com - June 7 at 9:29 AM
finance.yahoo.com logoLuminex Corporation's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan
finance.yahoo.com - June 5 at 9:45 AM
finance.yahoo.com logoPatterson Companies Grapples With Multiple Issues: Dump Now?
finance.yahoo.com - June 2 at 7:43 PM
americanbankingnews.com logoG Walter Loewenbaum II Sells 25,000 Shares of Luminex Co. (LMNX) Stock
www.americanbankingnews.com - June 1 at 4:29 PM
finance.yahoo.com logoThermo Fisher on an Acquisition Spree, Competition Rife
finance.yahoo.com - May 30 at 10:14 AM
finance.yahoo.com logoVarian Medical at a 52-Week High: What's Driving the Stock?
finance.yahoo.com - May 30 at 10:14 AM
finance.yahoo.com logoInogen (INGN) Hits a 52-Week High on Solid Q1, Upbeat View
finance.yahoo.com - May 30 at 10:14 AM
finance.yahoo.com logoNuVasive Aims for Innovation, Global Growth amid Woes
finance.yahoo.com - May 30 at 10:14 AM
finance.yahoo.com logoQuintiles IMS Holdings (Q) to Repurchase 10.6M Common Share
finance.yahoo.com - May 30 at 10:14 AM
finance.yahoo.com logoIDEXX Laboratories Global Growth Solid amid Currency Woes
finance.yahoo.com - May 30 at 10:14 AM
americanbankingnews.com logoLuminex Co. (LMNX) to Issue $0.06 Quarterly Dividend
www.americanbankingnews.com - May 25 at 6:50 PM
americanbankingnews.com logoLuminex Co. (LMNX) Director G Walter Loewenbaum II Sells 25,000 Shares
www.americanbankingnews.com - May 25 at 1:22 PM
finance.yahoo.com logoLuminex Corporation Declares Second Quarter Cash Dividend
finance.yahoo.com - May 24 at 11:07 AM
finance.yahoo.com logoIntegra LifeSciences to Offer aap's LOQTEQ System in the US
finance.yahoo.com - May 24 at 11:07 AM
finance.yahoo.com logoLabCorp Offers Sera's PreTRM to Assess Preterm Birth Risk
finance.yahoo.com - May 24 at 11:07 AM
americanbankingnews.com logoLuminex Co. (LMNX) Upgraded by TheStreet to "B-"
www.americanbankingnews.com - May 23 at 5:34 PM
finance.yahoo.com logoBruker Corp (BRKR) at 52-Week High: What's Driving the Stock?
finance.yahoo.com - May 23 at 10:43 AM
finance.yahoo.com logoIDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects
finance.yahoo.com - May 23 at 10:43 AM
finance.yahoo.com logoHologic (HOLX) Poised on Balanced Growth Amid Currency Woes
finance.yahoo.com - May 23 at 10:43 AM
finance.yahoo.com logoIntuitive Surgical at 52-Week High: What's Driving the Stock?
finance.yahoo.com - May 22 at 10:20 AM
americanbankingnews.com logoLuminex Co. (LMNX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 19 at 12:52 PM
finance.yahoo.com logoHalyard Health Announces New Drainage System, Stock Down
finance.yahoo.com - May 18 at 8:54 AM

Social

Chart

Luminex Corporation (LMNX) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff